SCHEMBL364772

SCHEMBL364772

COC(=O)c1ccc(Oc2ccc(Cl)c(C(F)(F)F)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 7/20 0.53
BRAF P15056 6/20 0.53
HDAC1 Q13547 3/20 0.53
HDAC3 O15379 2/20 0.53
HDAC4 P56524 2/20 0.53
HDAC7 Q8WUI4 2/20 0.53
HDAC2 Q92769 2/20 0.53
HDAC10 Q969S8 2/20 0.53
HDAC11 Q96DB2 2/20 0.53
HDAC8 Q9BY41 2/20 0.53
HDAC6 Q9UBN7 2/20 0.53
HDAC9 Q9UKV0 2/20 0.53
HDAC5 Q9UQL6 2/20 0.53
ARAF P10398 2/20 0.53
KDR P35968 2/20 0.52
NOTUM Q6P988 3/20 0.50
CHEK2 O96017 1/20 0.50
LMNA P02545 2/20 0.49
SCN5A Q14524 1/20 0.47
SCN9A Q15858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16320297 0.87 ESRRA (0.52) RAF1BRAFHDAC1HDAC3HDAC4
SCHEMBL9106278 0.86 ESRRA (0.57) RAF1BRAFHDAC1HDAC3HDAC4
SCHEMBL197395 0.85 NOTUM (0.62) KDRNOTUMLMNAPDGFRBCA7
SCHEMBL16319732 0.85 SCN9A (0.48) RAF1BRAFHDAC1HDAC3HDAC4
SCHEMBL16319599 0.85 SCN9A (0.52) RAF1BRAFHDAC1HDAC3HDAC4
SCHEMBL365495 0.84 PLA2G7 (0.53) RAF1BRAFHDAC1HDAC3HDAC4
SCHEMBL364213 0.83 CHEK2 (0.64) RAF1BRAFHDAC1HDAC3HDAC4
SCHEMBL371116 0.81 SCN9A (0.67) RAF1BRAFHDAC1HDAC3HDAC4
SCHEMBL19668099 0.79 RAF1 (0.80) RAF1BRAFARAFKDRLMNA
SCHEMBL371059 0.79 RAF1 (0.44) RAF1BRAFHDAC1HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593427-B1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2014-12-24 EP disclosed
EP-2593427-A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN Pfizer Limited (GB) 2013-05-22 EP disclosed
WO-2012007883-A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LIMITED (GB) 2012-01-19 WO disclosed
WO-2012007883-A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LIMITED (GB) 2012-01-19 WO disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010207-A1 Chemical Compounds SCN1A, SCN1B, SCN7A RAF1 183/4885BRAF 514/4885HDAC1 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.